

CURRICILUM VITAE

Leonidas Benetatos MD, PhD

Ioannina 01 April 2025

Surname: Benetatos

First name: Leonidas

Place and Date of Birth: 31 March 1973

Preveza, GREECE,

Nationality: Greek

Languages: Greek (native), English, Italian

Tel: +306937191370; +302682361222

Fax: +302682024837

e-mail: benetatosleon@yahoo.com; leonidas.benetatos@prevezahospital.gr

EDUCATION

1990: High school, Preveza, Greece

1998: Faculty of Medicine and Surgery, University of BOLOGNA, ITALY (October 1991-May 1998)

QUALIFICATIONS

1. Faculty of Medicine and Surgery, University of BOLOGNA, ITALY, 1998
2. Italian state licensing exam in practicing medical profession, University of BOLOGNA, ITALY, 1999
3. Medical Specialization title of Hematology, IOANNINA, GREECE, 2010

PREVIOUS POSTS

July 1999- October 1999: Clinical training in Internal Medicine, Cardiology, and Surgery, General Hospital of Preveza, Greece.

November 1999-May 2001: Rural Medical Service, and Clinical training in Cardiology, Department Cardiology and Coronary Care Unit, General Hospital of Preveza, Greece.

June 2001-February 2003: Clinical training in Internal Medicine, Department of Internal Medicine, General Hospital of Preveza, Greece.

March 2003-August 2003: Military Service in the Greek Army as field medical officer.

November 2003-January 2006: Clinical fellow, in Hematology, Department

of Hematology, University Hospital of Ioannina,
Greece.

January 2006-July 2010: Resident in Hematology, Department of Hematology,
University Hospital of Ioannina, Greece

January 2011- 26 July 2011: Attendant in Hematology, Department of
Hematology, University Hospital of Ioannina, Greece

27 July 2011- 10 March 2025: Consultant in Hematology, Blood Bank, General
Hospital of Preveza, Greece

10 March 2025-to date: Assistant Professor of hematology, Faculty of Medicine,
School of Health Sciences, University of Ioannina, Greece

MEMBERSHIP

Member of the Hellenic Hematology Association.

Member of ERIC.

GRADUATION THESIS

Substitution treatment with testosterone; novel applications

Leonidas Benetatos, Prof. Renato Pasquali

PhD THESIS

Cell differentiation and gene methylation in hematological malignancies

Leonidas Benetatos, Prof. Konstantinos Bourantas

INTERNATIONAL COLABORATIONS

1. University of **Washington, Seattle, USA** studying the origins of Greek DNA,
February 2015.

PI: Prof. George Stamatoyannopoulos.

2. University of Philadelphia (Computational Medicine Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

With Prof. Isidoros Rigoutsos publishing:

Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol Life Sci. 2013 Mar;70(5):795-814.

Partecipation in Clinical Trials

1. «Μελέτη της μεθυλίωσης των ανασταλτών των κινασών που εξαρτώνται από τις κυκλίνες σε ασθενείς με μονοκλωνικές γαμμαπάθειες»
Επιστημονικός υπεύθυνος: Επίκουρη Καθηγήτρια Παθολογίας Σταυρούλα Τσιάρα.
Αριθμός μελέτης: 80021 Πανεπιστήμιο Ιωαννίνων.
Χορηγός: Πανεπιστήμιο Ιωαννίνων.
2. «Μελέτη της μεθυλίωσης γονιδίων που σχετίζονται με την ογκογένεση σε ασθενείς με αιματολογικές κακοήθειες»
Επιστημονικός υπεύθυνος: Καθηγητής Αιματολογίας-Παθολογίας Κωνσταντίνος Μπουραντάς
Αριθμός μελέτης: 22130 Πανεπιστήμιο Ιωαννίνων.
Χορηγοί: Genesis Pharma, Roche, Jannsen-Cilag.
3. «Μια αναδρομική και προοπτική μελέτη παρατήρησης για την εξέταση της διαχείρισης της υποστηρικτικής φροντίδας ασθενών με non-Hodgkinλέμφωμα (NHL) οι οποίοι αντιμετωπίζονται με CHOP-14 ή 21 (με ή χωρίς Rituximab)-20060297».
Επιστημονικός υπεύθυνος: Καθηγητής Αιματολογίας-Παθολογίας Κωνσταντίνος Μπουραντάς
Χορηγός: Genesis Pharma
4. «Πρόγραμμα ευρείας χορήγησης του EXJADE (deferasirox) σε ασθενείς με συγγενείς διαταραχές των ερυθροκυττάρων και χρόνια υπερφόρτωση σιδήρου που οφείλεται σε μεταγγίσεις αίματος, οι οποίοι δεν μπορούν να αντιμετωπιστούν επαρκώς με τις άλλες χηλικές ενώσεις δέσμευσης του σιδήρου που έχουν λάβει έγκριση κυκλοφορίας στη χώρα τους-CICL670A2203».
Επιστημονικός υπεύθυνος: Καθηγητής Αιματολογίας-Παθολογίας Κωνσταντίνος Μπουραντάς
Χορηγός: Novartis
5. «Τυχαιοποιημένη, συγκριτική ανοιχτή μελέτη φάσης III σχετικά με την αποτελεσματικότητα και την ασφάλεια της μακροχρόνιας θεραπείας με ICL670 (5 mg/kg/day έως 40 mg/kg/day) σε σύγκριση με δεφεροξαμίνη (20

mg/kg/day έως 60 mg/kg/day) σε ασθενείς με β-μεσογειακή αναιμία και αποσιδήρωση από μεταγγίσεις- C1CL670A0107».

Επιστημονικός υπεύθυνος: Καθηγητής Αιματολογίας-Παθολογίας
Κωνσταντίνος Μπουραντάς

Χορηγός: Novartis

6. «Πολυκεντρική αναδρομική μη παρεμβατική μελέτη καταγραφής δεδομένων θεραπείας ασθενών με πολλαπλό μυέλωμα που έχουν αντιμετωπισθεί με λεναλιδομίδη (Revlimid) σύμφωνα με την καθιερωμένη κλινική πρακτική-CC-5013-PAS-001».

Επιστημονικός υπεύθυνος: Καθηγητής Αιματολογίας-Παθολογίας
Κωνσταντίνος Μπουραντάς

Χορηγός: Genesis Pharma

7. Συνεργασία για την κλινική μελέτη της εταιρείας Novartis

CABL001J12302(ASC4 START)για ενήλικους συμμετέχοντες (ηλικίας ≥18 ετών) με νεοδιαγνωσμένη θετική στο χρωμόσωμα της Φιλαδέλφειας χρόνια μυελογενή λευχαιμία σε χρόνια φάση (Ph+ CML-CP), EudraCT EU Trial Number: 2022-000995-21; clinicaltrials.gov identifier: NCT05456191

Χορηγός: Novartis

Υπεύθυνη Καθηγήτρια: Ελένη Καψάλη

ABSTRACTS

1. Alymara V., **Benetatos L.**, Karali K., Chaidos A., Tzouvara E., Vassou A., Bourantas KL.

Thalassemia intermedia and malignant lymphoma: a report of two cases

9th Congress of the European Hematology Association. Geneva, Switzerland 10-13 June 2004.

2. Chaidos A., **Benetatos L.**, Alymara V., Vassou A., Tsiara S., Hatzimichael E., Bourantas KL.

Low-dose thalidomide and corticosteroids for the treatment of chronic idiopathic myelofibrosis

9th Congress of the European Hematology Association. Geneva, Switzerland 10-13 June 2004.

3. **Benetatos L.**, Chaidos A., Alymara V., Vassou A., Bourantas K.L.

Correlation of serum erythropoietin levels with deferiprone and desferrioxamine in thalassemic patients

10th Congress of the European Hematology Association. Stockholm, Sweden, 2-5 June 2005.

4. **Benetatos L.**, Dasoula A., Hatzimichael E., Georgiou I., Vassou A., Syrrou M., Bourantas K.

Epigenetic modifications of the dlk1/gtl 2 imprinted genes in multiple myeloma and Waldenstrom's macroglobulinemia; preliminary results
11th Congress of the European Hematology Association. Amstrerdam, Netherlands, 15-18 June 2006.

5. **Benetatos L.**, Dasoula A., Hatzimichael E., Georgiou I., Kapsali E., Bourantas K., Syrou M.
Epigenetic alterations in dlk1/gtl 2 imprinting status in myelodysplastic syndromes; preliminary results.
11th Congress of the European Hematology Association. Amstrerdam, Netherlands, 15-18 June 2006.
6. Hatzimichael E., Vassou A., **Benetatos L.**, Bourantas L., Tsiara ST., Bourantas K.
Safety and efficacy of a combination regimen containing pentostatin, chlorambucil and methylprednisolone in elderly patients with progressing chronic lymphocytic leukemia.
11th Congress of the European Hematology Association. Amstrerdam, Netherlands, 15-18 June 2006.
7. Kouskou F., **Benetatos L.**, Alymara V., Bassou A., Bourantas KL.
Thrombophilic mutation in thalassemia and $\beta(0)$ - thalassemia.
11th Congress of the European Hematology Association. Amstrerdam, Netherlands, 15-18 June 2006.
8. E. Hatzimichael, A. Dasoula, **L. Benetatos**, A. Vassou, I. Georgiou, M. Syrou, KL. Bourantas.
Methylation status of p57kip2 and p16ink4 in patients with plasma cell neoplasms.
12th Congress of the European Hematology Association. Vienna, Austria, 7-10 June 2007.
9. V. Tsiora, E. Hatzimichael, A. Vassou, **L. Benetatos**, V. Zina, K. Skandalis, E. Oikonomou, E. Kapsali, KL Bourantas.
Immune thrombocytopenic purpura: a 10 year experience from a single center.
12th Congress of the European Hematology Association. Vienna, Austria, 7-10 June 2007.
- E. Hatzimichael, K. Maki, A. Dasoula, **L. Benetatos**, E. Lambri, A. Vassou, M. Syrou, K. Bourantas
Methylation of the von Hippel-Lindau tumor suppressor gene is a frequent event in plasma cell neoplasias
13th Congress of the European Hematology Association, Copenhagen, Denmark, June 12-15, 2008.
11. E. Kapsali, Ch. Tsaousi, E. Hatzimichael, **L. Benetatos**, K. Bourantas
Impact of mean platelet volume on survival of patients with myelodysplastic syndromes
13th Congress of the European Hematology Association, Copenhagen, Denmark, June 12-15, 2008.

12. E. Hatzimichael, A. Dasoula, **L. Benetatos**, J. Stebbing, G. Dranitsaris, K. Bourantas
VHL methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.
 Lymphoma & Myeloma. October 16-18 2008, New York, USA.
13. E. Hatzimichael, A. Dasoula, **L. Benetatos**, S. Tsiara, I. Georgiou, J. Stebbing, G. Dranitsaris, K. Bourantas
Absence of TP73 promoter methylation in patients with multiple myeloma and Waldenstrom's macroglobulinemia
 Lymphoma & Myeloma. October 16-18 2008, New York, USA.
14. E. Hatzimichael, A. Dasoula, R. Shah, N. Syed, **L. Benetatos**, K. Bourantas G. Dranitsaris, T. Crook
The prolyl hydroxylase EGLN3 is frequently methylated in plasma cell Neoplasms.
 Lymphoma & Myeloma. October 16-18 2008, New York, USA.
15. A. Dasoula, E. Hatzimichael, G. Dranitsaris, **L. Benetatos**, N. Syed, A. Vassou, J. Stebbing, T. Crook, K. Bourantas
Snk/Plk2 CpG methylation in patients with multiple myeloma
 ASCO Meeting Abstracts , Orlando, Florida, May 20 2009: e19532
16. E. Kapsali, Ch. Tsaousi, **L. Benetatos**, P. Bouranta, K. Bourantas
Acute myeloid leukemia and bleeding disorders at diagnosis. A single center experience
 14th Congress of the European Hematology Association, Berlin, Germany, June 4-7, 2009.
17. **L. Benetatos**, A. Dasoula, E. Hatzimichael, G. Dranitsaris, M. Voukelatou, S. Tsiara, I. Georgiou, K. Bourantas
Methylation analysis of the SNRPN and MEG3 imprinted genes in acute myeloid leukemia patients
 14th Congress of the European Hematology Association, Berlin, Germany, June 4-7, 2009.
18. **L. Benetatos**, E. Hatzimichael, G. Dranitsaris, A. Dasoula, M. Syrou, S. Tsiara, G. Vartholomatos, M. Voukelatou, K. Bourantas
Promoter hypermethylation status of the MEG3 and SNRPN imprinted genes in myelodysplastic syndromes
 14th Congress of the European Hematology Association, Berlin, Germany, June 4-7, 2009.
19. A. Vassou, E. Hatzimichael, A. Dasoula, **L. Benetatos**, K. Zaharopoulou, L. Kefala, K. Bourantas
Methylation of von Hippel-Lindau gene in chronic lymphocytic leukemia (CLL)
 14th Congress of the European Hematology Association, Berlin, Germany, June

4-7, 2009.

20. A. Vassou, A. Dasoula, **L. Benetatos**, E. Hatzimichael, L. Kefala, K. Zaharopoulou, K. Bourantas
Epigenetic alteration in DLK1/MEG3 imprinting genes in chronic lymphocytic leukemia (CLL)
14th Congress of the European Hematology Association, Berlin, Germany, June 4-7, 2009.
21. A. Dasoula, E. Hatzimichael, **L. Benetatos**, N. Syed, G. Dranitsaris, J. Stebbing, T. Crook, K. Bourantas
Study of specific genetic and epigenetic variables in multiple myeloma.
Lymphoma & Myeloma. October 22-24 2009, New York, USA.

PUBLICATIONS

1. **Benetatos L**, Vartholomatos G.
Embryonic transcription and epigenetics: root of the evil.
Hum Cell. 2023 Sep;36(5):1830-1833.
2. . . Hatzimichael E, Timotheatou D, Koumpis E, **Benetatos L**, Makis A.
Luspatercept: A New Tool for the Treatment of Anemia Related to β -Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.
Diseases. 2022 Oct 9;10(4):85
3. Epialleles and epialleleic heterogeneity in hematological malignancies.
Benetatos L, Benetatou A, Vartholomatos G
Med Oncol. 2022 in press corrected proof
4. Long non-coding RNAs and MYC association in hematological malignancies.
Benetatos L, Benetatou A, Vartholomatos G.
Ann Hematol. 2020 Oct;99(10):2231-2242.
5. Enhancers and MYC interplay in hematopoiesis.
Benetatos L, Benetatou A, Vartholomatos G.
J Mol Med (Berl). 2020 Apr;98(4):471-481.
6. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L, Vartholomatos G.
Cell Mol Life Sci. 2018 Jun;75(11):1999-2009
7. The crosstalk between long non-coding RNAs and PI3K in cancer.
Benetatos L, Voulgaris E, Vartholomatos G.
Med Oncol. 2017 Mar;34(3):39.

8. Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.
Benetatos L.
Leuk Lymphoma. 2017 Feb;58(2):503-504.
9. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.
Benetatos L, Vartholomatos G.
Ann Hematol. 2016 Oct;95(10):1571-82.
10. Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.
Benetatos L, Vartholomatos G.
Leukemia. 2015 Feb 23. doi: 10.1038/leu.2015.47.
11. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist.
Benetatos L, Vartholomatos G, Hatzimichael E.
Cell Mol Life Sci. 2014 Nov;71(22):4421-30.
12. Delta-like homologue 1 and its role in the bone marrow niche and hematologic malignancies.
Benetatos L, Hatzimichael E.
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):451-5.
13. miR-29b: a new demethylator in multiple myeloma.
Benetatos L.
Cell Cycle. 2013 Dec 15;12(24):3718-9.
14. Polycomb group proteins and MYC: the cancer connection.
Benetatos L, Vartholomatos G, Hatzimichael E.
Cell Mol Life Sci. 2014 Jan;71(2):257-69.
15. MicroRNAs mark in the MLL-rearranged leukemia.
Benetatos L, Vartholomatos G.
Ann Hematol. 2013 Nov;92(11):1439-50.
16. Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael E, Georgiou G, **Benetatos L**, Briasoulis E.
Am J Blood Res. 2013;3(1):29-51.
17. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome.
Benetatos L, Voulgaris E, Vartholomatos G, Hatzimichael E.
Int J Cancer. 2013 Jul 15;133(2):267-74.
18. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.
Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E.
Cell Mol Life Sci. 2013 Mar;70(5):795-814.

19. Asymptomatic T-cell large granular lymphocyte leukemia with an unusual immunophenotype.
 Petsa PK, Karamoutsios A, Dova L, **Benetatos L**, Petsiou A, Kolaitis N, Georgopoulos A, Vartholomatos G.
 Clin Pract. 2012 Jun 27;2(3):e68.
20. DLK1-MEG3 imprinted domain microRNAs in cancer biology.
Benetatos L, Voulgaris E, Vartholomatos G.
 Crit Rev Eukaryot Gene Expr. 2012;22(1):1-15.
21. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.
 Hatzimichael E, Dasoula A, Kounnis V, **Benetatos L**, Lo Nigro C, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T.
 Leuk Lymphoma. 2012 Sep;53(9):1709-13.
22. Deregulated microRNAs in multiple myeloma.
Benetatos L, Vartholomatos G.
 Cancer. 2012 Feb 15;118(4):878-87.
23. MEG3 imprinted gene contribution in tumorigenesis.
Benetatos L, Vartholomatos G, Hatzimichael E.
 Int J Cancer. 2011 Aug 15;129(4):773-9.
24. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL, Crook T.
 Ann Hematol. 2011 Sep;90(9):1037-45.
25. Study of specific genetic and epigenetic variables in multiple myeloma.
 Hatzimichael E, Dasoula A, **Benetatos L**, Syed N, Dranitsaris G, Crook T, Bourantas K.
 Leuk Lymphoma. 2010 Dec;51(12):2270-4.
26. Flow cytometric immunophenotyping for the diagnosis of a rare T-LGL neoplasm.
 Vartholomatos G, **Benetatos L**.
 J Postgrad Med. 2010 Jul-Sep;56(3):255.
27. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL.
 Leuk Res. 2010 Feb;34(2):148-53.
28. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.

- Hatzimichael E, Dranitsaris G, Dasoula A, **Benetatos L**, Stebbing J, Crook T, Bourantas KL.
Clin Lymphoma Myeloma. 2009 Jun;9(3):239-42.
29. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.
Hatzimichael E, **Benetatos L**, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I, Syrrou M, Stebbing J, Coley HM, Crook T, Bourantas KL.
Leuk Res. 2009 Sep;33(9):1272-5.
 30. Peripheral blood flow cytometry based diagnosis in primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: implications for more extensive use.
Benetatos L, Dova L, Baxevanos G, Kolaitis NI, Bourantas KL, Vartholomatos G.
Cytometry B Clin Cytom. 2009 Mar;76(2):102-6.
 31. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma.
Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL.
Clin Lymphoma Myeloma. 2008 Jun;8(3):171-5.
 32. Large B-cell transformation of chronic lymphocytic leukemia presenting as a penile mass.
Vassou A, Bai M, **Benetatos L**, Tsili A, Bourantas K.
Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):199-200.
 33. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms.
Hatzimichael E, Dasoula A, **Benetatos L**, Makis A, Stebbing J, Crook T, Syrrou M, Bourantas KL.
Br J Haematol. 2008 May;141(4):557-8.
 34. Malignancies in beta-thalassemia patients: a single-center experience and a concise review of the literature.
Benetatos L, Alymara V, Vassou A, Bourantas KL.
Int J Lab Hematol. 2008 Apr;30(2):167-72.
 35. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes.
Benetatos L, Dasoula A, Syed N, Hatzimichael E, Crook T, Bourantas KL.
Leukemia. 2008 Jun;22(6):1293-5.
 36. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
Benetatos L, Hatzimichael E, Vassou A, Bourantas KL.
Leuk Res. 2007 Jan;31(1):119-20.

37. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.
Hatzimichael E, **Benetatos L**, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL.
Clin Lab Haematol. 2006 Dec;28(6):416-8.
38. Non-secretory multiple myeloma with involvement of the hand as initial manifestation.
Benetatos L, Alymara V, Chaidos A, Vassou A, Bourantas KL.
Leuk Lymphoma. 2006 Aug;47(8):1677-9.
39. Effectiveness of rituximab as prophylaxis in thrombotic thrombocytopenic purpura.
Benetatos L, Vassou A, Bourantas KL.
Clin Lab Haematol. 2006 Aug;28(4):288-9. No abstract available.
40. Rituximab as first line treatment for MALT lymphoma of extraocular muscles.
Benetatos L, Alymara V, Asproudis I, Bourantas KL.
Ann Hematol. 2006 Sep;85(9):625-6.
41. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
Benetatos L, Chaidos A, Alymara V, Vassou A, Bourantas KL.
Eur J Haematol. 2005 Mar;74(3):273-4. Erratum in: Eur J Haematol. 2005 Aug;75(2):183.

REVIEWER IN PEER-REVIEW JOURNALS

1. Blood
2. Leukemia
3. Cancer
4. Leukemia Research
5. Epigenomics
6. International Journal of Cancer
7. Expert opinion on drug safety
8. Expert opinion on biological therapy
9. Cellular Physiology and Biochemistry
10. Tumor Biology
11. Journal of hematology and Oncology
12. DNA and Cell Biology
13. PLOS One
14. British Journal of Cancer

15. Cell death and disease

ATTENDED MEETINGS

1. 10th Congress of the European Hematology Association. Stockholm, Sweden, 2-5 June 2005.
2. 12th Congress of the European Hematology Association. Vienna, Austria, 7-10 June 2007.
3. 34rd Annual meeting of the European group for blood and marrow transplantation. Florence, Italy, March 30- April 2, 2008.
4. The multiple myeloma debates. Madrid, Spain, 25-26 September 2008.
5. The International conference of medical oncology. Bucharest, Romania, 09-12 October 2008.
6. Now we know T-cell lymphomas better. Bologna, Italy, 16-18 March 2009.
7. 14th Congress of the European Hematology Association. Berlin, Germany, 4-7 June 2009.
8. The 11th International symposium on myelodysplastic syndromes. Edinburgh, UK, 18-21 May 2011.
9. 53th ASH Annual Meeting San Diego, CA, USA, December 2011
10. 17th Congress of the European Hematology Association. Amsterdam, Netherlands, 14-17 June 2012.
11. 19th Congress of the European Hematology Association. Milan, Italy, 12-15 June 2014.
12. 56th ASH Annual Meeting San Francisco, CA, USA, 6-9 December 2014
13. 20th Congress of the European Hematology Association. Vienna, Austria 11-14 June 2015.
14. 57th American Society of Hematology annual meeting. Orlando, Florida, USA, 5-8 December 2015
15. 42nd Annual Meeting of the European Society for Blood and Marrow Transplanation. Valencia, Spain, 3-6 April 2016.
16. 58th American Society of Hematology annual meeting. San Diego, California, USA, 3-6 December 2016.

17. “Challenges in CLL today”. University of Rome “Sapienza” 26-27 October 2017.
18. 44nd Annual Meeting of the European Society for Blood and Marrow Transplantation. Lisbon, Portugal, 18-21 March 2018.
19. 23th Congress of the European Hematology Association. Stockholm, Sweden 14-17 June 2018.
20. Highlights of American Society of Hematology in the Mediterranean. Athens 15-16 March 2019.
21. 27th Congress of the European Hematology Association. Vienna, Austria 9-17 June 2022.
22. ERIC 2022 Meeting: New frontiers in CLL research. Barcelona , Spain 6-8 October 2022.
23. 9th World Congress on Controversies in Multiple Myeloma. Paris, France, 11-14 May 2023
24. 28th Congress of the European Hematology Association. Frankfurt, Germany 8-15 June 2023.